MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer

被引:51
|
作者
Goorts, Briete X. Z. [1 ,2 ,3 ]
Dreuning, Kelly M. A. [2 ]
Houwers, Janneke B. [3 ]
Kooreman, Loes F. S. [1 ,4 ]
Boerma, Evert-Jan G. [5 ]
Mann, Ritse M. [6 ]
Lobbes, Marc B. I. [1 ,3 ]
Smidt, Marjolein L. [1 ,2 ]
机构
[1] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Surg, Maastricht, Netherlands
[3] Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, POB 5800, NL-6202 AZ Maastricht, Netherlands
[4] Maastricht Univ, Med Ctr, Dept Pathol, Maastricht, Netherlands
[5] Zuyderland Med Ctr, Dept Surg, Sittard Geleen, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Radiol & Nucl Med, Nijmegen, Netherlands
来源
BREAST CANCER RESEARCH | 2018年 / 20卷
关键词
Breast Cancer; Neoadjuvant chemotherapy; Magnetic resonance imaging; RECOMMENDATIONS; THERAPY; UPDATE; TRIAL;
D O I
10.1186/s13058-018-0950-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability.& para;& para;Methods: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included. All breast tumors were reassessed on MRI by two experienced breast radiologists and classified into six patterns: type 0 (complete radiologic response); type 1 (concentric shrinkage); type 2 (crumbling); type 3 (diffuse enhancement); type 4 (stable disease); type 5 (progressive disease). Percentages of tumors showing pathological complete response (pCR), > 50% tumor reduction and > 50% tumor diameter reduction per MRI-based response pattern were calculated. Correlation between MRI-based response patterns and pathological tumor reduction was studied with Pearson's correlation coefficient, and interobserver agreement was tested with Cohen's Kappa.& para;& para;Results: Patients (n = 76; mean age 53, range 29-72 years) with 80 tumors (4 bilateral) were included. There was significant correlation between these MRI-based response patterns halfway through NAC and tumor reduction on pathology assessment (reader 1 r = 0.33; p = 0.003 and reader 2 r = 0.45; p < 0.001). Type-0, type-1 or type-2 patterns halfway through NAC showed highest tumor reduction rates on pathology assessment, with > 50% tumor reduction in 90%, 78% and 65% of cases, respectively. In 83% of tumors with type 0 halfway through NAC, pathology assessment showed pCR. There was no significant correlation between MRI-based response patterns after NAC and tumor reduction rates on pathology assessment (reader 1 r = - 0.17; p = 0.145 and reader 2 r = - 0.17; p = 0.146). In 41% of tumors with type 0 after NAC, pathology assessment showed pCR.& para;& para;Conclusion: MRI-based response patterns halfway through NAC can predict pathologic response more accurately than MRI-based response patterns after NAC. Complete radiological response halfway NAC is associated with 83% pCR, while complete radiological response after NAC seems to be correct in only 41% of cases.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
    Briete Goorts
    Kelly M. A. Dreuning
    Janneke B. Houwers
    Loes F. S. Kooreman
    Evert-Jan G. Boerma
    Ritse M. Mann
    Marc B. I. Lobbes
    Marjolein L. Smidt
    Breast Cancer Research, 20
  • [2] Multicontrast MRI-based radiomics for the prediction of pathological complete response to neoadjuvant chemotherapy in patients with early triple negative breast cancer
    Angeline Nemeth
    Pierre Chaudet
    Benjamin Leporq
    Pierre-Etienne Heudel
    Fanny Barabas
    Olivier Tredan
    Isabelle Treilleux
    Agnès Coulon
    Frank Pilleul
    Olivier Beuf
    Magnetic Resonance Materials in Physics, Biology and Medicine, 2021, 34 : 833 - 844
  • [3] Multicontrast MRI-based radiomics for the prediction of pathological complete response to neoadjuvant chemotherapy in patients with early triple negative breast cancer
    Nemeth, Angeline
    Chaudet, Pierre
    Leporq, Benjamin
    Heudel, Pierre-Etienne
    Barabas, Fanny
    Tredan, Olivier
    Treilleux, Isabelle
    Coulon, Agnes
    Pilleul, Frank
    Beuf, Olivier
    MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE, 2021, 34 (06) : 833 - 844
  • [4] MRI in diagnosis of pathological complete response in breast cancer patients after neoadjuvant chemotherapy
    Li, Yan-Ling
    Zhang, Xiao-Peng
    Li, Jie
    Cao, Kun
    Cui, Yong
    Li, Xiao-Ting
    Sun, Ying-Shi
    EUROPEAN JOURNAL OF RADIOLOGY, 2015, 84 (02) : 242 - 249
  • [5] Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study
    Wang, Kun
    Huang, Yuhong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Can MRI predict the response to neoadjuvant chemotherapy in breast cancer accurately?
    Fatayer, H.
    Kim, B.
    Daii, B.
    Sharma, N.
    Manuel, D.
    Shabaan, A.
    Perren, T.
    Velikova, G.
    Horgan, K.
    Lansdown, M.
    CANCER RESEARCH, 2012, 72
  • [7] Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
    Freitas, Ana Julia Aguiar de
    Causin, Rhafaela Lima
    Varuzza, Muriele Bertagna
    Hidalgo Filho, Cassio Murilo Trovo
    Silva, Vinicius Duval da
    Souza, Cristiano de Padua
    Marques, Marcia Maria Chiquitelli
    CANCERS, 2021, 13 (21)
  • [8] Can mammographic breast density predict complete pathological response in patients with locally advanced breast cancer following neoadjuvant chemotherapy?
    Agarwal, Veenoo
    Spalding, Lisa
    Blick, Tony
    Thompson, Erik W.
    Dobrovic, Alexander
    Redfern, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 65 - 65
  • [9] Pathological Complete Response Patients after Neoadjuvant Chemotherapy in Breast Cancer
    Takaoka, Megumi
    Ohsumi, Shozo
    Ikejiri, Haruka
    Shidahara, Tomohiro
    Miyoshi, Yuichiro
    Takahashi, Mina
    Takashima, Seiki
    Aogi, Kenjiro
    ACTA MEDICA OKAYAMA, 2022, 76 (02) : 105 - 111
  • [10] Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy
    Montemurro, Filippo
    Di Cosimo, Serena
    BREAST, 2014, 23 (05): : 690 - 691